These results indicate that simple, easy-to-use AID technology, such as Omnipod 5, can be adopted by a broad population of people with type 2 diabetes, potentially improving their lives.

Insulet Corp.’s PODD groundbreaking Omnipod 5 Automated Insulin Delivery (“AID”) system (Omnipod 5) received the FDA’s approval for use by type 2 diabetes patients (ages 18 years and above).

"As we work to reach more people with our innovative, tubeless Omnipod 5 AID System, today’s announcement represents yet another significant step forward for our Company and our customers." ...

Insulet Corp. PODD announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s ABT FreeStyle Libre 2 Plus continuous glucose monitoring (CGM ...

(RTTNews) - Insulet Corp. (PODD), a provider of tubeless insulin pump technology, announced Wednesday that the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott ...

today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This ...

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...